1,704
+7.37%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nxera Pharma Co
Its shares trade on Tokyo Stock Exchange under the ticker 4565.T. It has been listed since 29 July 2004. In the fiscal year to 31 December 2025, it reported revenue of ¥29.61bn and a net loss of ¥12.53bn. At that date it held total assets of ¥134.79bn and shareholders' equity of ¥61.00bn.
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Jul 2004
- Employees
- 190
- Website
- soseiheptares.com ↗
Leadership
Pay as last reported
- Dr. Shinichi TamuraChairman of the Board, since 1990
- Mr. Christopher CargillPresident, Representative Executive Officer, Chief Executive Officer, President of Subsidiary, Director, since 2018¥312.0m
- Mr. Hironoshin NomuraChief Financial Officer, Executive Vice President
- Mr. Toshihiro MaedaChief Operating Officer, Executive Vice President
- Mr. Kieran JohnsonExecutive Vice President, Chief Accounting Officer¥104.0m
- Mr. Kazuhiko YoshizumiExecutive Vice President, Chief Compliance Officer
- Dr. Matthew BarnesExecutive Vice President, President of Subsidiary¥105.0m
- Ms. Candelle ChongExecutive Vice President, Manager of Chief Executive Officer's Office
- Dr. Satoshi TanakaExecutive Vice President
- Mr. Kuniaki KagaIndependent Director
- Mr. Noriaki NagaiIndependent Director
- Dr. David RoblinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 41
- Social
- 38
- Governance
- 80
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sosei Group Corp possesses several core strengths that contribute to its competitive advantage and market position. These strengths include a strong portfolio of innovative drug candidates, advanced drug discovery capabilities, and strategic partnerships with renowned pharmaceutical companies. These factors provide the company with a solid foundation for continued growth and success.
Weaknesses
- Despite its strengths, Sosei Group Corp also faces certain weaknesses that could hinder its performance. One notable weakness is the inherent risk and regulatory challenges associated with drug development and the lengthy approval process. Additionally, the company primarily operates in the highly competitive pharmaceutical industry, which necessitates continuous investments in research and development to stay ahead of competitors.
Opportunities
- Sosei Group Corp has significant opportunities for strategic growth and expansion. The increasing global demand for innovative therapeutics, particularly in areas such as oncology and neurology, presents a fertile market for the company to capitalize on. Furthermore, the growing trend of collaborations and partnerships in the pharmaceutical industry offers Sosei Group Corp the chance to leverage its expertise and forge alliances with key players, potentially unlocking new avenues for revenue generation.
Threats
- Like any other business operating in the pharmaceutical sector, Sosei Group Corp faces a range of external threats that could impact its performance. These threats include intense competition from both established pharmaceutical companies and emerging biotech startups, as well as the risk of patent expirations for existing drugs. Additionally, regulatory changes or delays in the approval process may pose challenges to the company's ability to bring its innovative drug candidates to market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.